Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).


Journal

Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353

Informations de publication

Date de publication:
17 01 2019
Historique:
received: 30 07 2018
accepted: 18 12 2018
entrez: 19 1 2019
pubmed: 19 1 2019
medline: 23 7 2019
Statut: epublish

Résumé

Clinical studies suggest that obesity, in addition to promoting breast cancer aggressiveness, is associated with a decrease in chemotherapy efficacy, although the mechanisms involved remain elusive. As chemotherapy is one of the main treatments for aggressive or metastatic breast cancer, we investigated whether adipocytes can mediate resistance to doxorubicin (DOX), one of the main drugs used to treat breast cancer, and the mechanisms associated. We used a coculture system to grow breast cancer cells with in vitro differentiated adipocytes as well as primary mammary adipocytes isolated from lean and obese patients. Drug cellular accumulation, distribution, and efflux were studied by immunofluorescence, flow cytometry, and analysis of extracellular vesicles. Results were validated by immunohistochemistry in a series of lean and obese patients with cancer. Adipocytes differentiated in vitro promote DOX resistance (with cross-resistance to paclitaxel and 5-fluorouracil) in a large panel of human and murine breast cancer cell lines independently of their subtype. Subcellular distribution of DOX was altered in cocultivated cells with decreased nuclear accumulation of the drug associated with a localized accumulation in cytoplasmic vesicles, which then are expelled into the extracellular medium. The transport-associated major vault protein (MVP), whose expression was upregulated by adipocytes, mediated both processes. Coculture with human mammary adipocytes also induced chemoresistance in breast cancer cells (as well as the related MVP-induced DOX efflux) and their effect was amplified by obesity. Finally, in a series of human breast tumors, we observed a gradient of MVP expression, which was higher at the invasive front, where tumor cells are at close proximity to adipocytes, than in the tumor center, highlighting the clinical relevance of our results. High expression of MVP in these tumor cells is of particular interest since they are more likely to disseminate to give rise to chemoresistant metastases. Collectively, our study shows that adipocytes induce an MVP-related multidrug-resistant phenotype in breast cancer cells, which could contribute to obesity-related chemoresistance.

Identifiants

pubmed: 30654824
doi: 10.1186/s13058-018-1088-6
pii: 10.1186/s13058-018-1088-6
pmc: PMC6337862
doi:

Substances chimiques

Antineoplastic Agents 0
RNA, Small Interfering 0
Vault Ribonucleoprotein Particles 0
major vault protein 0
Doxorubicin 80168379AG
Paclitaxel P88XT4IS4D
Fluorouracil U3P01618RT

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7

Références

J Clin Oncol. 2008 Sep 1;26(25):4072-7
pubmed: 18757321
Pigment Cell Melanoma Res. 2015 Jul;28(4):464-75
pubmed: 25950383
Cancer Lett. 2012 Nov 28;324(2):142-51
pubmed: 22643115
NPJ Breast Cancer. 2017 May 3;3:19
pubmed: 28649659
Int J Obes (Lond). 2009 Sep;33(9):978-90
pubmed: 19564875
PLoS One. 2012;7(2):e30804
pubmed: 22319589
Cancer Res. 2011 Apr 1;71(7):2455-65
pubmed: 21459803
Nat Rev Immunol. 2011 Feb;11(2):85-97
pubmed: 21252989
Int J Cancer. 2002 Jan 10;97(2):149-56
pubmed: 11774257
Cytotechnology. 1996;19(3):191-7
pubmed: 8862006
Am J Pathol. 1996 Mar;148(3):877-87
pubmed: 8774142
Blood. 1997 May 15;89(10):3745-54
pubmed: 9160680
Anticancer Res. 2005 Nov-Dec;25(6B):3905-15
pubmed: 16312045
Anticancer Res. 2000 Nov-Dec;20(6B):4373-7
pubmed: 11205274
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Cancer Res. 2005 Dec 1;65(23):10862-71
pubmed: 16322233
Nat Med. 1995 Jun;1(6):578-82
pubmed: 7585126
Eur J Cancer. 2004 Mar;40(4):594-605
pubmed: 14962729
J Natl Cancer Inst. 1999 Oct 6;91(19):1647-53
pubmed: 10511592
Br J Cancer. 1996 Mar;73(5):596-602
pubmed: 8605092
JCI Insight. 2017 Feb 23;2(4):e87489
pubmed: 28239646
Mol Cancer Ther. 2007 Jun;6(6):1804-13
pubmed: 17575109
Cell Mol Life Sci. 2009 Jan;66(1):43-61
pubmed: 18759128
Anticancer Res. 2003 May-Jun;23(3B):2657-64
pubmed: 12894554
J Clin Oncol. 2016 Dec 10;34(35):4203-4216
pubmed: 27903149
PLoS One. 2014 Feb 06;9(2):e88193
pubmed: 24516610
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
Dis Model Mech. 2015 Mar;8(3):237-51
pubmed: 25633981
Biochemistry. 1996 Mar 5;35(9):2811-7
pubmed: 8608115
Curr Opin Cell Biol. 2015 Oct;36:13-22
pubmed: 26183445
Cancer Prev Res (Phila). 2017 Apr;10(4):235-243
pubmed: 28270386
Cancer Res. 2016 Jul 15;76(14):4051-7
pubmed: 27216185
PLoS One. 2015 Dec 18;10(12):e0144359
pubmed: 26684197
Oncotarget. 2017 May 20;8(34):57622-57641
pubmed: 28915700
Am J Pathol. 1996 Apr;148(4):1237-47
pubmed: 8644864
J Biol Chem. 1998 Apr 10;273(15):8971-4
pubmed: 9535882
Cancer Res. 2013 Sep 15;73(18):5657-68
pubmed: 23903958
J Cell Sci. 1993 Sep;106 ( Pt 1):23-9
pubmed: 8270627
Oncogene. 2003 Oct 20;22(47):7458-67
pubmed: 14576851
J Clin Invest. 2012 Nov;122(11):4243-56
pubmed: 23041627
Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G602-10
pubmed: 12909565
Cancer Res. 2003 Aug 1;63(15):4331-7
pubmed: 12907600
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
pubmed: 2359136
Breast Cancer Res. 2015 Apr 24;17:57
pubmed: 25908175
Cancer Prev Res (Phila). 2012 Jul;5(7):930-42
pubmed: 22588949
Cancer Res. 2000 Jan 1;60(1):47-50
pubmed: 10646850
Cancer Res. 1993 Apr 1;53(7):1475-9
pubmed: 7680954
Clin Cancer Res. 2003 Feb;9(2):827-36
pubmed: 12576456
Breast Cancer Res Treat. 2010 Jan;119(1):145-53
pubmed: 19731015
J Cell Sci. 2006 Feb 1;119(Pt 3):459-69
pubmed: 16418217
Curr Opin Biotechnol. 2012 Dec;23(6):972-7
pubmed: 22677067
Cancer Genomics Proteomics. 2012 May-Jun;9(3):153-61
pubmed: 22593250
Nat Rev Cancer. 2010 Feb;10(2):147-56
pubmed: 20075923
Am J Pathol. 1998 Feb;152(2):373-8
pubmed: 9466563
Biochem Biophys Res Commun. 2011 Jul 22;411(1):102-6
pubmed: 21712027
Ann Oncol. 2014 Oct;25(10):1901-14
pubmed: 24769692

Auteurs

Camille Lehuédé (C)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.
Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse, INSERM, UPS, Toulouse, France.

Xia Li (X)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.
Present address: Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Stéphanie Dauvillier (S)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.

Charlotte Vaysse (C)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.
Département de Chirurgie Oncologique, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Camille Franchet (C)

Service d'Anatomo-Pathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Emily Clement (E)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.

David Esteve (D)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.

Mélanie Longué (M)

Département de Biostatistiques, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Léonor Chaltiel (L)

Département de Biostatistiques, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Sophie Le Gonidec (S)

Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse, INSERM, UPS, Toulouse, France.

Ikrame Lazar (I)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.

Aline Geneste (A)

Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052/CNRS, Lyon, France.

Charles Dumontet (C)

Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM UMR 1052/CNRS, Lyon, France.

Philippe Valet (P)

Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse, INSERM, UPS, Toulouse, France.

Laurence Nieto (L)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.

Frédérique Fallone (F)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France. frederique.fallone@ipbs.fr.

Catherine Muller (C)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France. muller@ipbs.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH